Evaluation of multiple consensus criteria for autoimmune encephalitis and temporal analysis of symptoms in a pediatric encephalitis cohort.

autoimmune encephalitis diagnostic criteria infectious encephalitis neuroimmune disease pediatric neurology temporal analysis and evaluation

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2022
Historique:
received: 25 05 2022
accepted: 29 08 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

To evaluate the sensitivity and specificity of current criteria for the diagnosis of autoimmune encephalitis (AE) and the temporal onset of neuropsychiatric symptoms (NP) in a pediatric encephalitis cohort. Multiple criteria for AE have been developed, including the Graus and pediatric-focused Cellucci consensus criteria, and the Determining Etiology in Encephalitis (DEE) score for patients with encephalitis. Early identification and treatment of AE is crucial to improve outcomes, but this can be difficult given the frequent overlap of clinical presentation between AE and infectious encephalitis (IE). A retrospective review was conducted of patients seen at our institution from 2000 to 2021 with a final diagnosis of AE or IE. These were narrowed through multiple exclusions to etiology-confirmed IE or antibody-positive/negative AE. Time of onset or results of all symptoms and diagnostics were recorded. Sensitivity and specificity of each criterion under various clinical scenarios were calculated over the first month after initial NP symptom onset. A total of 23 antibody-positive AE, 9 antibody-negative AE and 23 IE patients were included in final analysis. Under an idealized scenario with rapid initial diagnostic evaluations, the sensitivity for pediatric AE by day 28 after onset of NP symptoms approached 90% for both Cellucci and Graus criteria. Specificity within these 28 days was low without infectious testing results, increasing the greatest with rapid PCR testing and second with infectious antibody testing-reaching ~90% with both. A DEE score of 3 provided a specificity of 100% in identifying IE, but low sensitivity (29%). Symptoms were noted to cluster within several days of onset in IE, but in AE were spread out. Personality/behavioral change, speech change, affective disorder, and sleep disturbance were noted more often in AE, while fever, elevated C-reactive protein or CSF protein, and abnormal MRI-Brain occurred more often in IE. In this study, we provide the first evaluation of the Cellucci criteria and the first validation of the DEE score in the differentiation of pediatric AE and IE. Further refinement of AE criteria is needed to improve early detection and treatment of pediatric AE.

Sections du résumé

Objective UNASSIGNED
To evaluate the sensitivity and specificity of current criteria for the diagnosis of autoimmune encephalitis (AE) and the temporal onset of neuropsychiatric symptoms (NP) in a pediatric encephalitis cohort.
Background UNASSIGNED
Multiple criteria for AE have been developed, including the Graus and pediatric-focused Cellucci consensus criteria, and the Determining Etiology in Encephalitis (DEE) score for patients with encephalitis. Early identification and treatment of AE is crucial to improve outcomes, but this can be difficult given the frequent overlap of clinical presentation between AE and infectious encephalitis (IE).
Design/methods UNASSIGNED
A retrospective review was conducted of patients seen at our institution from 2000 to 2021 with a final diagnosis of AE or IE. These were narrowed through multiple exclusions to etiology-confirmed IE or antibody-positive/negative AE. Time of onset or results of all symptoms and diagnostics were recorded. Sensitivity and specificity of each criterion under various clinical scenarios were calculated over the first month after initial NP symptom onset.
Results UNASSIGNED
A total of 23 antibody-positive AE, 9 antibody-negative AE and 23 IE patients were included in final analysis. Under an idealized scenario with rapid initial diagnostic evaluations, the sensitivity for pediatric AE by day 28 after onset of NP symptoms approached 90% for both Cellucci and Graus criteria. Specificity within these 28 days was low without infectious testing results, increasing the greatest with rapid PCR testing and second with infectious antibody testing-reaching ~90% with both. A DEE score of 3 provided a specificity of 100% in identifying IE, but low sensitivity (29%). Symptoms were noted to cluster within several days of onset in IE, but in AE were spread out. Personality/behavioral change, speech change, affective disorder, and sleep disturbance were noted more often in AE, while fever, elevated C-reactive protein or CSF protein, and abnormal MRI-Brain occurred more often in IE.
Conclusion UNASSIGNED
In this study, we provide the first evaluation of the Cellucci criteria and the first validation of the DEE score in the differentiation of pediatric AE and IE. Further refinement of AE criteria is needed to improve early detection and treatment of pediatric AE.

Identifiants

pubmed: 36237630
doi: 10.3389/fneur.2022.952317
pmc: PMC9552833
doi:

Types de publication

Journal Article

Langues

eng

Pagination

952317

Informations de copyright

Copyright © 2022 Pointon, Ward, Yeshokumar, Piquet, Schreiner and Kammeyer.

Déclaration de conflit d'intérêts

Unrelated to this study: Author AP reports grants from University of Colorado and Rocky Mountain MS Center, consulting fees from Genentech/Roche and Alexion, and also receive honorarium from Medlink and publication royalties from Springer as co-editor of a textbook. Author RK reports grants from University of Colorado and Rocky Mountain MS Center and consulting fees from Sanofi-Genzyme. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
J Neuroradiol. 2023 May;50(3):288-292
pubmed: 35662572
Sci Rep. 2020 Oct 26;10(1):18291
pubmed: 33106568
BMC Neurol. 2017 Nov 6;17(1):195
pubmed: 29110638
Zhonghua Er Ke Za Zhi. 2022 Aug 2;60(8):786-791
pubmed: 35922189
Pediatrics. 2015 Apr;135(4):e974-84
pubmed: 25802349
Lancet Psychiatry. 2019 Mar;6(3):235-246
pubmed: 30765329
J Child Neurol. 2016 Nov;31(13):1450-1456
pubmed: 27270468
Mediators Inflamm. 2015;2015:792578
pubmed: 25873770
Front Neurol. 2021 May 14;12:601761
pubmed: 34054682
J Biomed Sci. 2019 Aug 8;26(1):57
pubmed: 31395054
J Neurol. 2019 Apr;266(4):1007-1015
pubmed: 30741377
J Child Neurol. 2020 Aug;35(9):591-599
pubmed: 32458722
Ann Neurol. 2020 Jul;88(1):148-159
pubmed: 32314416
Ann Clin Transl Neurol. 2022 Aug;9(8):1125-1135
pubmed: 35713518
Neurology. 2019 Jan 15;92(3):e244-e252
pubmed: 30578370
Neuropsychiatr Dis Treat. 2020 Nov 04;16:2649-2660
pubmed: 33177828
Neurology. 2021 Dec 7;97(23):e2262-e2268
pubmed: 34635560
Anal Cell Pathol (Amst). 2019 Dec 3;2019:9684175
pubmed: 31886122
Brain Behav. 2021 Aug;11(8):e2277
pubmed: 34232562
Medicina (B Aires). 2017;77(3):214-221
pubmed: 28643679
Front Neurol. 2018 Jun 08;9:434
pubmed: 29951031
Clin Infect Dis. 2013 Oct;57(8):1114-28
pubmed: 23861361
Dev Med Child Neurol. 2017 Dec;59(12):1256-1260
pubmed: 28972277
N Engl J Med. 1999 Sep 23;341(13):936-42
pubmed: 10498488
Neurology. 2022 Apr 5;98(14):e1489-e1498
pubmed: 35145006
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Front Neurol. 2019 Feb 13;10:25
pubmed: 30814971
Curr Opin Neurol. 2015 Jun;28(3):283-7
pubmed: 25923127
Eur J Paediatr Neurol. 2021 Jan;30:82-87
pubmed: 33461084
Ital J Pediatr. 2019 Dec 18;45(Suppl 3):162
pubmed: 31849329
J Neurol. 2018 Mar;265(3):586-596
pubmed: 29356973
Dev Med Child Neurol. 2022 May;64(5):649-653
pubmed: 34724211
Front Microbiol. 2018 Nov 20;9:2751
pubmed: 30515139
Front Neurol. 2019 Aug 22;10:906
pubmed: 31507515
Epilepsia. 2022 Jul;63(7):1658-1670
pubmed: 35340020
Clin Infect Dis. 2012 Apr;54(7):899-904
pubmed: 22281844
J Neuroimmunol. 2018 Oct 15;323:62-72
pubmed: 30196836
Front Neurol. 2020 Sep 09;11:960
pubmed: 33013639
Psychol Med. 2019 Dec;49(16):2709-2716
pubmed: 30560745
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(2):
pubmed: 31953309

Auteurs

Tiffany Pointon (T)

Section of Child Neurology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States.

Ryan Ward (R)

School of Medicine, University of Colorado, Aurora, CO, United States.

Anusha Yeshokumar (A)

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Amanda Piquet (A)

Section of Neuroimmunology, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, United States.

Teri Schreiner (T)

Section of Child Neurology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States.
Section of Neuroimmunology, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, United States.

Ryan Kammeyer (R)

Section of Child Neurology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States.
Section of Neuroimmunology, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, United States.

Classifications MeSH